Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Braun, S; Cevatli, BS; Assemi, C; Janni, W; Kentenich, CRM; Schindlbeck, C; Rjosk, D; Hepp, F
   Comparative analysis of micrometastasis to the bone marrow and lymph nodesof node-negative breast cancer patients receiving no adjuvant therapy
   JOURNAL OF CLINICAL ONCOLOGY
   
   S. Braun et al., "Comparative analysis of micrometastasis to the bone marrow and lymph nodesof node-negative breast cancer patients receiving no adjuvant therapy", J CL ONCOL, 19(5), 2001, pp. 1468-1475
2. Braun, S; Pantel, K; Muller, P; Janni, W; Hepp, F; Kentenich, CRM; Gastroph, S; Wischnik, A; Dimpfl, T; Kindermann, G; Riethmuller, G; Schlimok, G
   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
   NEW ENGLAND JOURNAL OF MEDICINE
   
   S. Braun et al., "Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.", N ENG J MED, 342(8), 2000, pp. 525-533
3. Braun, S; Hepp, F; Kentenich, CRM; Janni, W; Pantel, K; Riethmuller, G; Willgeroth, F; Sommer, HL
   Monoclonal antibody therapy with Edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells inbone marrow
   CLINICAL CANCER RESEARCH
   
   S. Braun et al., "Monoclonal antibody therapy with Edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells inbone marrow", CLIN CANC R, 5(12), 1999, pp. 3999-4004
4. BRAUN S; KENTENICH CRM; JANNI W; HEPP F; DEWAAL J; SOMMER HL
   EVALUATION OF BONE-MARROW MICROMETASTASES AS POTENTIAL SURROGATE MARKER FOR EFFICACY OF ADJUVANT TREATMENT
   European journal of cancer
   
   S. Braun et al., "EVALUATION OF BONE-MARROW MICROMETASTASES AS POTENTIAL SURROGATE MARKER FOR EFFICACY OF ADJUVANT TREATMENT", European journal of cancer, 34, 1998, pp. 43-43